Comparative Computational Analysis of Natural Compounds Against SARS-CoV-2 Spike Protein Structural Conformations
The SARS-CoV-2 Spike glycoprotein plays a critical role in viral entry into host cells through its interaction with the human angiotensin-converting enzyme 2 (ACE2), making it an important target for antiviral drug discovery. This study employed an integrated computational approach to investigate the binding potential of twenty natural compounds against two experimentally determined SARS-CoV-2 Spike protein structures (PDB IDs: 6M17 and 7A91). Molecular docking identified Amentoflavone as the most favourable ref-erence compound against both structures, with binding energies of -10.4 and -9.8 kcal/mol, respectively. Further evaluation of Amentoflavone analogues identified A63 (CHEMBL187504) as a promising candidate, exhibiting more favourable docking scores of approximately -11.3 kcal/mol against 6M17 and -10.1 kcal/mol against 7A91. Molecular dynamics simulations over 100 ns revealed structure-dependent differences in conforma-tional behaviour, residue flexibility, protein compactness, solvent exposure and intermo-lecular hydrogen-bond persistence. MM-PBSA calculations further indicated favourable binding free energies for all four investigated complexes, with 6M17-Amentoflavone (-78.450 ± 13.922 kJ/mol) and 7A91-A63 (-80.769 ± 16.410 kJ/mol) exhibiting the most fa-vourable energetic profiles for their respective structures. Energy decomposition high-lighted van der Waals and electrostatic interactions as major favourable contributors, while residue-wise analysis identified potential amino acid interaction hotspots involved in ligand stabilisation. Overall, the findings demonstrate that Amentoflavone and its ana-logue A63 exhibit promising, structure-dependent computational binding profiles against SARS-CoV-2 Spike protein structures. These findings provide a basis for further structural optimisation and experimental investigations to establish their potential to interfere with Spike-mediated viral entry.
Authors
- Fidele Ntie‐Kang (ORCID: https://orcid.org/0000-0003-0795-394X)
- Angelina I. Makaye (ORCID: https://orcid.org/0000-0002-6965-8658)
- Yoshua B. Mtulo (ORCID: https://orcid.org/0009-0003-5751-8070)
- Lucas Paul
Publication Details
- Journal
- Preprints.org
- Published
- 2026-11-13
- DOI
- https://doi.org/10.20944/preprints202611.1436.v1
- Primary Topic
- Computational Drug Discovery Methods
- Type
- preprint